ECSP067013A - 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 - Google Patents
2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4Info
- Publication number
- ECSP067013A ECSP067013A EC2006007013A ECSP067013A ECSP067013A EC SP067013 A ECSP067013 A EC SP067013A EC 2006007013 A EC2006007013 A EC 2006007013A EC SP067013 A ECSP067013 A EC SP067013A EC SP067013 A ECSP067013 A EC SP067013A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- cycloalkyl
- hydroxyalkyl
- quinolil
- oxazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La invención reivindica compuestos de fórmula Ien la cual es un heteroarilo de 5 miembros; X es S u O;R1 es H, alquilo, cicloalquilo, cicloalquilalquilo-, -CH2F, -CHF2, -CF3, -C(O)alquilo o -C(O)NR18R19;R3 y R4 son H, alquilo, hidroxialquilo o -C(O)Oalquilo;R5 y R6 son H, alquilo, hidroxialquilo, alcoxialquilo, mercaptoalquilo, -CH2F, -CHF2, -CF3, -C(O)OH o -C(O)Oalquilo;R7 es H, alquilo, alquenilo, hidroxialquilo, cicloalquilo, alcoxialquilo, aminoalquilo, (R17-fenil)alquilo o -CH2-C(O)-O-alquilo; y R8 comprende alquilo, heteroarilo, fenilo o cicloalquilo, o heterocicloalquilo, todos sustituidos en forma opcional, o una amida cicloalquil- o heterocicloalquil-sustituida; o R7 y R8 y el nitrógeno al cual están unidos forman conjuntamente un anillo sustituido en forma opcional; y las restantes variables son como se definen en la memoria descriptiva. También se reivindican composiciones farmacéuticas, el uso de los compuestos como inhibidores de PDE4 y combinaciones con otros activos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57226604P | 2004-05-18 | 2004-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP067013A true ECSP067013A (es) | 2006-12-29 |
Family
ID=35106691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006007013A ECSP067013A (es) | 2004-05-18 | 2006-11-17 | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 |
Country Status (20)
Country | Link |
---|---|
US (1) | US7511062B2 (es) |
EP (1) | EP1758883B1 (es) |
JP (1) | JP4584990B2 (es) |
KR (1) | KR100907354B1 (es) |
CN (1) | CN1984901B (es) |
AR (1) | AR055192A1 (es) |
AT (1) | ATE531705T1 (es) |
AU (1) | AU2005247906B2 (es) |
BR (1) | BRPI0511295A (es) |
CA (1) | CA2565599C (es) |
EC (1) | ECSP067013A (es) |
IL (1) | IL179280A (es) |
MX (1) | MXPA06013414A (es) |
NO (1) | NO20065830L (es) |
NZ (1) | NZ551017A (es) |
PE (1) | PE20060241A1 (es) |
RU (1) | RU2417993C9 (es) |
TW (1) | TWI286475B (es) |
WO (1) | WO2005116009A1 (es) |
ZA (1) | ZA200609277B (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8145182B2 (en) * | 2004-05-07 | 2012-03-27 | Interdigital Technology Corporation | Supporting emergency calls on a wireless local area network |
KR101122359B1 (ko) | 2004-05-07 | 2012-03-23 | 인터디지탈 테크날러지 코포레이션 | 무선 근거리 통신망의 긴급 호 지원 |
US8682279B2 (en) | 2004-05-07 | 2014-03-25 | Interdigital Technology Corporation | Supporting emergency calls on a wireless local area network |
EP2484382A1 (en) * | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
AU2006332945C1 (en) * | 2005-12-23 | 2013-02-28 | Wyeth | Modified lysine-mimetic compounds |
JP5152518B2 (ja) * | 2006-03-10 | 2013-02-27 | 日産化学工業株式会社 | 置換イソキサゾリン化合物及び有害生物防除剤 |
WO2007132307A1 (en) * | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
JP5352452B2 (ja) * | 2006-06-06 | 2013-11-27 | メディシノバ, インコーポレイテッド | 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法 |
US8138205B2 (en) * | 2006-07-07 | 2012-03-20 | Kalypsys, Inc. | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
WO2008006051A2 (en) * | 2006-07-07 | 2008-01-10 | Govek Steven P | Bicyclic heteroaryl inhibitors of pde4 |
KR20090026217A (ko) * | 2006-07-11 | 2009-03-11 | 쉐링 코포레이션 | 치환된 5-옥사졸-2-일-퀴놀린 화합물의 크시나포에이트 염 |
ITMI20061581A1 (it) * | 2006-08-04 | 2008-02-05 | Univ Bari | Ligandi del recettore beta-3 adrenergico e loro uso in terapia |
KR20090040378A (ko) | 2006-08-14 | 2009-04-23 | 쉐링 코포레이션 | 2-(퀴놀린-5-일)-4,5 이치환된-아졸 유도체의 합성을 위한 방법 및 중간체 |
US7956189B2 (en) * | 2006-08-14 | 2011-06-07 | Schering Corporation | Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore |
EP2061796A2 (en) | 2006-09-15 | 2009-05-27 | Schering Corporation | Azetidine and azetidinone derivatives useful in treating pain and disorders of lipid metabolism |
AR062790A1 (es) | 2006-09-15 | 2008-12-03 | Schering Corp | Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos |
AR062841A1 (es) * | 2006-09-15 | 2008-12-10 | Schering Corp | Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos |
US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
JP2008260691A (ja) * | 2007-04-10 | 2008-10-30 | Bayer Cropscience Ag | 殺虫性アリールイソオキサゾリン誘導体 |
JP4986927B2 (ja) * | 2007-05-14 | 2012-07-25 | 大塚製薬株式会社 | 医薬 |
WO2008157205A2 (en) * | 2007-06-15 | 2008-12-24 | Duke University | Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
EP2176257A2 (en) * | 2007-07-10 | 2010-04-21 | Schering Corporation | Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof |
CN101796049A (zh) * | 2007-07-10 | 2010-08-04 | 先灵公司 | 制备取代的5-喹啉基-噁唑及其药学上可接受的盐的方法 |
GB2451629A (en) * | 2007-08-06 | 2009-02-11 | Univ Sheffield | 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones |
US8569282B2 (en) | 2007-12-11 | 2013-10-29 | Cytopathfinder, Inc. | Carboxamide compounds and their use |
PL2098526T3 (pl) | 2008-02-22 | 2014-06-30 | Neurotune Ag | Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu |
AR074318A1 (es) | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
TWI396689B (zh) * | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶10抑制劑之吡衍生物 |
JP5476895B2 (ja) | 2008-12-17 | 2014-04-23 | セントラル硝子株式会社 | ヒドロキシル基置換生成物の製造方法 |
EP2375899B1 (en) * | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
US8796297B2 (en) | 2009-06-30 | 2014-08-05 | Abbvie Inc. | 4-substituted-2-amino-pyrimidine derivatives |
US8435976B2 (en) * | 2009-09-08 | 2013-05-07 | F. Hoffmann-La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
CN102625807B (zh) * | 2009-09-08 | 2016-03-09 | 霍夫曼-拉罗奇有限公司 | 4-取代的吡啶-3-基-甲酰胺化合物和使用方法 |
KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
MA34300B1 (fr) * | 2010-05-13 | 2013-06-01 | Amgen Inc | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 |
JP5709101B2 (ja) * | 2010-09-01 | 2015-04-30 | 東レ・ファインケミカル株式会社 | ヒドロキシプロリン誘導体の製造法 |
JP5916730B2 (ja) * | 2010-09-06 | 2016-05-11 | グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス,チャイニーズ アカデミー オブ サイエンスィズ | アミド化合物 |
WO2012072512A1 (en) | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists |
CN102408433B (zh) * | 2011-10-20 | 2014-04-09 | 天津药物研究院 | 含嘧啶的肟类化合物、其制备方法和用途 |
US8530461B2 (en) * | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
AR090836A1 (es) * | 2012-04-24 | 2014-12-10 | Chugai Pharmaceutical Co Ltd | Derivados de benzamida |
CN104379568A (zh) | 2012-04-24 | 2015-02-25 | 中外制药株式会社 | 喹唑啉二酮衍生物 |
US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
RU2737434C2 (ru) | 2013-03-13 | 2020-11-30 | Форма Терапьютикс, Инк. | Новые соединения и композиции для ингибирования fasn |
ES2700541T3 (es) | 2013-03-14 | 2019-02-18 | Univ Columbia | Octahidrociclopentapirroles, su preparación y uso |
US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
US10273243B2 (en) | 2013-03-14 | 2019-04-30 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
AU2014338070A1 (en) | 2013-10-23 | 2016-05-05 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
WO2015161830A1 (en) * | 2014-04-25 | 2015-10-29 | Sunshine Lake Pharma Co., Ltd. | Heteroaromatic derivatives and pharmaceutical applications thereof |
WO2015168286A1 (en) | 2014-04-30 | 2015-11-05 | The Trustees Of Columbia University In The City Of New York | Substituted 4-phenylpiperidines, their preparaiton and use |
GB201415569D0 (en) * | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
JP2018016544A (ja) * | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ[2.2.2]オクタン誘導体 |
CN104829492A (zh) * | 2015-05-06 | 2015-08-12 | 河北工业大学 | 一种反式N-Boc-1,3-环丁二胺的制备方法 |
CN106279138B (zh) * | 2015-12-29 | 2019-03-01 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物中的应用 |
GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
AU2018380132B2 (en) | 2017-12-06 | 2023-11-09 | Lin Bioscience, Inc. | Tubulin inhibitors |
EP3746422A4 (en) | 2018-02-01 | 2021-06-09 | The University Of Sydney | ANTI-CANCER COMPOUNDS |
KR20200004573A (ko) * | 2018-07-04 | 2020-01-14 | 고려대학교 세종산학협력단 | 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물 |
CA3106385A1 (en) * | 2018-09-13 | 2020-03-19 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
CN112079791A (zh) * | 2020-08-21 | 2020-12-15 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用 |
CN116963773A (zh) | 2021-01-21 | 2023-10-27 | 浙江养生堂天然药物研究所有限公司 | ***的组合物及方法 |
WO2023147468A1 (en) * | 2022-01-28 | 2023-08-03 | BioAge Labs, Inc. | N-oxide inhibitors of nlrp3 inflammasome |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK283162B6 (sk) * | 1996-05-20 | 2003-03-04 | Darwin Discovery Limited | Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom |
CA2252501A1 (en) * | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
US6069151A (en) * | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
DE69723863T2 (de) * | 1996-11-06 | 2004-04-15 | Darwin Discovery Ltd., Slough | Chinoline und deren therapeutische verwendung |
ATE247652T1 (de) * | 1999-03-29 | 2003-09-15 | Neurogen Corp | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
US6569885B1 (en) * | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
GB0003254D0 (en) * | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
AU2001277723A1 (en) * | 2000-08-11 | 2002-02-25 | Nippon Chemiphar Co., Ltd. | Ppardelta activators |
WO2002076957A1 (fr) * | 2001-03-23 | 2002-10-03 | Nippon Chemiphar Co.,Ltd. | Activateur de recepteur active par les proliferateurs du peroxysome |
DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
KR20090026217A (ko) * | 2006-07-11 | 2009-03-11 | 쉐링 코포레이션 | 치환된 5-옥사졸-2-일-퀴놀린 화합물의 크시나포에이트 염 |
-
2005
- 2005-05-16 KR KR1020067024186A patent/KR100907354B1/ko not_active IP Right Cessation
- 2005-05-16 MX MXPA06013414A patent/MXPA06013414A/es active IP Right Grant
- 2005-05-16 EP EP05750076A patent/EP1758883B1/en active Active
- 2005-05-16 RU RU2006144709/04A patent/RU2417993C9/ru not_active IP Right Cessation
- 2005-05-16 WO PCT/US2005/017134 patent/WO2005116009A1/en active Application Filing
- 2005-05-16 BR BRPI0511295-8A patent/BRPI0511295A/pt not_active IP Right Cessation
- 2005-05-16 US US11/130,359 patent/US7511062B2/en not_active Expired - Fee Related
- 2005-05-16 NZ NZ551017A patent/NZ551017A/en unknown
- 2005-05-16 AT AT05750076T patent/ATE531705T1/de active
- 2005-05-16 AU AU2005247906A patent/AU2005247906B2/en not_active Ceased
- 2005-05-16 CN CN2005800236668A patent/CN1984901B/zh not_active Expired - Fee Related
- 2005-05-16 CA CA2565599A patent/CA2565599C/en not_active Expired - Fee Related
- 2005-05-16 PE PE2005000540A patent/PE20060241A1/es not_active Application Discontinuation
- 2005-05-16 JP JP2007513471A patent/JP4584990B2/ja not_active Expired - Fee Related
- 2005-05-17 TW TW094115924A patent/TWI286475B/zh not_active IP Right Cessation
- 2005-05-17 AR ARP050102012A patent/AR055192A1/es not_active Application Discontinuation
-
2006
- 2006-11-07 ZA ZA200609277A patent/ZA200609277B/en unknown
- 2006-11-14 IL IL179280A patent/IL179280A/en not_active IP Right Cessation
- 2006-11-17 EC EC2006007013A patent/ECSP067013A/es unknown
- 2006-12-15 NO NO20065830A patent/NO20065830L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200602056A (en) | 2006-01-16 |
CN1984901B (zh) | 2011-02-09 |
EP1758883B1 (en) | 2011-11-02 |
IL179280A0 (en) | 2007-03-08 |
RU2417993C9 (ru) | 2011-10-10 |
CN1984901A (zh) | 2007-06-20 |
NO20065830L (no) | 2007-02-16 |
WO2005116009B1 (en) | 2006-01-26 |
EP1758883A1 (en) | 2007-03-07 |
RU2006144709A (ru) | 2008-06-27 |
ZA200609277B (en) | 2008-06-25 |
PE20060241A1 (es) | 2006-04-01 |
AU2005247906B2 (en) | 2011-08-25 |
IL179280A (en) | 2011-07-31 |
CA2565599C (en) | 2012-07-31 |
US20060106062A1 (en) | 2006-05-18 |
US7511062B2 (en) | 2009-03-31 |
MXPA06013414A (es) | 2007-01-23 |
AR055192A1 (es) | 2007-08-08 |
JP4584990B2 (ja) | 2010-11-24 |
KR100907354B1 (ko) | 2009-07-10 |
NZ551017A (en) | 2010-11-26 |
BRPI0511295A (pt) | 2007-12-04 |
ATE531705T1 (de) | 2011-11-15 |
TWI286475B (en) | 2007-09-11 |
AU2005247906A1 (en) | 2005-12-08 |
JP2007537300A (ja) | 2007-12-20 |
KR20070013306A (ko) | 2007-01-30 |
CA2565599A1 (en) | 2005-12-08 |
RU2417993C2 (ru) | 2011-05-10 |
WO2005116009A1 (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
CY1119101T1 (el) | Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
AR071644A1 (es) | Plaguicidas mesoionicos | |
AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
ECSP12006640A (es) | Inhibidores heterocíclicos de aspartil proteasa | |
PE20090042A1 (es) | Analogos de ciclopamina | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
BRPI0508966A (pt) | composto, composição farmacêutica, e, uso de um composto | |
CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
ES2531256T3 (es) | Amidas fungicidas | |
PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
PE20140171A1 (es) | Pirazoles fungicidas y sus mezclas | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR059925A1 (es) | Formulaciones | |
PE20140961A1 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
AR076264A1 (es) | Triazolopiridinas sustituidas y analogos de estas | |
AR065649A1 (es) | Dionas ciclicas herbicidamente activas, procesos de obtencion y composiciones. | |
PE20080925A1 (es) | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA) | |
PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
DE602006019221D1 (de) | Von dopamin-d3-rezeptoren |